Analysis of differentially expressed proteins in lymph fluids related to lymphatic metastasis in a breast cancer rabbit model guided by contrast‑enhanced ultrasound

Xu,Jiachao; Zhang,Xin; Yang,Guangfei; Sun,Wei; Wang,Wen; Mi,Chengrong

doi:10.3892/ol.2024.14276

Analysis of differentially expressed proteins in lymph fluids related to lymphatic metastasis in a breast cancer rabbit model guided by contrast‑enhanced ultrasound

Authors:
- Jiachao Xu
- Xin Zhang
- Guangfei Yang
- Wei Sun
- Wen Wang
- Chengrong Mi
View Affiliations

Affiliations: School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Department of Ultrasound, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750003, P.R. China, Department of Ultrasound, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750003, P.R. China
Published online on: February 6, 2024 https://doi.org/10.3892/ol.2024.14276
Article Number: 143
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify differentially expressed proteins in the lymph fluid of rabbits with breast cancer lymphatic metastasis compared with healthy rabbits and to analyze and verify these proteins using proteomics technologies. In the process of breast cancer metastasis, the composition of the lymph fluid will also change. Rabbits with breast cancer lymph node metastasis and normal rabbits were selected for analysis. Lymph fluid was extracted under the guidance of percutaneous contrast‑enhanced ultrasound. Label‑free quantitative proteomics was used to detect and compare differences between the rabbit cancer model and healthy rabbits and differential protein expression results were obtained. Bioinformatics analysis was performed using Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analysis software, selecting the most significantly differentially expressed proteins. Finally, parallel reaction monitoring technology was applied for validation. A total of 547 significantly differentially expressed proteins were found in the present study, which included 371 upregulated proteins and 176 downregulated proteins. The aforementioned genes were mainly involved in various cellular and metabolic pathways, including upregulated proteins, such as biliverdin reductase A and isocitrate dehydrogenase 2 and downregulated proteins, such as pyridoxal kinase. The upregulated proteins protein disulfide‑isomerase 3, protein kinase cAMP‑dependent type I regulatory subunit α and ATP‑binding cassette sub‑family C member 4 participated in immune regulation, endocrine regulation and anti‑tumor drug resistance regulation, respectively. Compared with healthy rabbits, rabbits with breast cancer metastasis differentially expressed of a number of different proteins in their lymph, which participate in the pathophysiological process of tumor occurrence and metastasis. Through further research, these differential proteins can be used as predictive indicators of breast cancer metastasis and new therapeutic targets.

View Figures

View References

1	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI
2	Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP and Zhu HP: Risk factors and preventions of breast cancer. Int J Biol Sci. 13:1387–1397. 2017. View Article : Google Scholar : PubMed/NCBI
3	Park M, Kim D, Ko S, Kim A, Mo K and Yoon H: Breast cancer metastasis: Mechanisms and therapeutic implications. Int J Mol Sci. 23:68062022. View Article : Google Scholar : PubMed/NCBI
4	Gouri A, Benarba B, Dekaken A, Aoures H and Benharkat S: Prediction of late recurrence and distant metastasis in early-stage breast cancer: Overview of current and emerging biomarkers. Curr Drug Targets. 21:1008–1025. 2020. View Article : Google Scholar : PubMed/NCBI
5	Yeo SK and Guan JL: Breast cancer: Multiple subtypes within a tumor? Trends Cancer. 3:753–760. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mani DR, Krug K, Zhang B, Satpathy S, Clauser KR, Ding L, Ellis M, Gillette MA and Carr SA: Cancer proteogenomics: Current impact and future prospects. Nat Rev Cancer. 22:298–313. 2022. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Kong X, Wang Z and Xuan L: Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment. J Cell Mol Med. 26:1351–1362. 2022. View Article : Google Scholar : PubMed/NCBI
8	du Bois H, Heim TA and Lund AW: Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Sci Immunol. 6:eabg35512021. View Article : Google Scholar : PubMed/NCBI
9	Arneth B: Tumor microenvironment. Medicina (Kaunas). 56:152019. View Article : Google Scholar : PubMed/NCBI
10	Rizzo A and Ricci AD: Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 31:549–555. 2022. View Article : Google Scholar : PubMed/NCBI
11	Cui Q, Dai L, Li J and Xue J: Accuracy of CEUS-guided sentinel lymph node biopsy in early-stage breast cancer: A study review and meta-analysis. World J Surg Oncol. 18:1122020. View Article : Google Scholar : PubMed/NCBI
12	Karaman S and Detmar M: Mechanisms of lymphatic metastasis. J Clin Invest. 124:922–928. 2014. View Article : Google Scholar : PubMed/NCBI
13	MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC and MacCoss MJ: Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26:966–968. 2010. View Article : Google Scholar : PubMed/NCBI
14	Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M and Cox J: The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 13:731–740. 2016. View Article : Google Scholar : PubMed/NCBI
15	Das S and Skobe M: Lymphatic vessel activation in cancer. Ann N Y Acad Sci. 113:235–241. 2008. View Article : Google Scholar
16	Liu Z, Wang R, Zhou J, Zheng Y, Dong Y, Luo T, Wang X and Zhan W: Ultrasound lymphatic imaging for the diagnosis of metastatic central lymph nodes in papillary thyroid cancer. Eur Radiol. 31:8458–8467. 2021. View Article : Google Scholar : PubMed/NCBI
17	Cha YJ, Kim ES and Koo JS: Amino acid transporters and glutamine metabolism in breast cancer. Int J Mol Sci. 19:9072018. View Article : Google Scholar : PubMed/NCBI
18	El Ansari R, McIntyre A, Craze ML, Ellis IO, Rakha EA and Green AR: Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 72:183–190. 2018. View Article : Google Scholar : PubMed/NCBI
19	Kim S, Kim DH, Jung WH and Koo JS: Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 20:339–348. 2013. View Article : Google Scholar : PubMed/NCBI
20	Craze ML, Cheung H, Jewa N, Coimbra NDM, Soria D, El-Ansari R, Aleskandarany MA, Wai Cheng K, Diez-Rodriguez M, Nolan CC, et al: MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer. 118:258–265. 2018. View Article : Google Scholar : PubMed/NCBI
21	Semenza GL: Hypoxia-inducible factors: Coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 36:252–259. 2017. View Article : Google Scholar : PubMed/NCBI
22	de Heer EC, Jalving M and Harris AL: HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer. J Clin Invest. 130:5074–5087. 2020. View Article : Google Scholar : PubMed/NCBI
23	Chichiarelli S, Altieri F, Paglia G, Rubini E, Minacori M and Eufemi M: ERp57/PDIA3: New insight. Cell Mol Biol Lett. 27:122022. View Article : Google Scholar : PubMed/NCBI
24	Hettinghouse A, Liu R and Liu CJ: Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol Ther. 181:34–48. 2018. View Article : Google Scholar : PubMed/NCBI
25	Song D, Liu H, Wu J, Gao X, Hao J and Fan D: Insights into the role of ERp57 in cancer. J Cancer. 12:2456–2464. 2021. View Article : Google Scholar : PubMed/NCBI
26	Park S, Park JH, Jung HJ, Jang JH, Ahn S, Kim Y, Suh PG, Chae S, Yoon JH, Ryu SH and Hwang D: A secretome profile indicative of oleate-induced proliferation of HepG2 hepatocellular carcinoma cells. Exp Mol Med. 50:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
27	Chen Y, Lin MC, Wang H, Chan CY, Jiang L, Ngai SM, Yu J, He ML, Shaw PC, Yew DT, et al: Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics. 7:3097–3104. 2007. View Article : Google Scholar : PubMed/NCBI
28	Li S, Zhao X, Chang S, Li Y, Guo M and Guan Y: ERp57-small interfering RNA silencing can enhance the sensitivity of drug-resistant human ovarian cancer cells to paclitaxel. Int J Oncol. 54:249–260. 2019.PubMed/NCBI
29	Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P: Molecular Biology of Osteosarcoma. Cancers (Basel). 12:21302020. View Article : Google Scholar : PubMed/NCBI
30	Pitsava G, Stratakis CA and Faucz FR: PRKAR1 and thyroid tumors. Cancers (Basel). 13:38342021. View Article : Google Scholar : PubMed/NCBI
31	Kirschner LS: PRKAR1A and the evolution of pituitary tumors. Mol Cell Endocrinol. 326:3–7. 2010. View Article : Google Scholar : PubMed/NCBI
32	Kochel TJ and Fulton AM: Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat. 116–117. 99–103. 2015.PubMed/NCBI
33	Huynh T, Norris MD, Haber M and Henderson MJ: ABCC4/MRP4: A MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol. 2:1782012. View Article : Google Scholar : PubMed/NCBI
34	Rasmuson A, Kock A, Fuskevåg OM, Kruspig B, Simón-Santamaría J, Gogvadze V, Johnsen JI, Kogner P and Sveinbjörnsson B: Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One. 7:e293312012. View Article : Google Scholar : PubMed/NCBI
35	Montani M, Hermanns T, Müntener M, Wild P, Sulser T and Kristiansen G: Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Arch. 462:437–443. 2013. View Article : Google Scholar : PubMed/NCBI